Skip to main content
Feature Story

Selecting CDK7

By Chris Cain, Senior Writer

Selecting CDK7

Selective inhibitors of cyclin dependent kinases have been hard to develop because the active sites of many family members are so similar. Now, a Harvard Medical School team has found a cyclin dependent kinase 7 inhibitor that covalently binds a cysteine residue outside the enzyme's kinase domain and suppresses leukemia in mice.1

Full Article

Today's Biotech & Pharma News

Profiles in Innovation

Subscribe Now
Free Trial